Clinical Trials Browser

INDUSTRY × Interventional × HER2 Negative Metastatic Breast Cancer × Clear all

NCT01948843 2016-04-14

Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer

Phase 1 Completed

HER2 Negative Metastatic Breast Cancer